Batman , I dont know what internal bickering you refer to . I wouldnt expect boards to agree on everything . Main thing here at this stage is the science , and its working , with the possibility to change the way we treat cancer . Moving ahead on three fronts on cancer , Rational Therapeutics assays on human tumours , the expanded preclinicals on the Imoxine/Coramsine combination and the completion of the phase 1 as a single agent , with a phase 2 announced for this year . Once they get into the phase 2 on their target of choice , against eariler stage cancers , I think the value of this company will be demonstrated beyond doubt . I dont think people realise how good the results from the phase 1 are . It is mainly a safety trial . It is random cancers and not the optimum target for the drug . The patients who volunteer are in the very last stages of their cancer and the doctors dont expect to see much improvement if any . To see any patients return to their normal life from here is fantastic and I dont know of any other Australian company to have achieved this . To have reached this stage , in quick time by biotech standards , on a shoe string budget , tells me management couldnt be too bad . What do you think? Cheers
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
